

REFERENCES

- [1] Grisham RN, Hyman DM, Iyer G. Targeted therapies for treatment of recurrent ovarian cancer. Clin Adv Hematol Oncol. 2014;12(3):158-162.
- [2] Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265-7279.
- [3] Kelland LR. Preclinical perspectives on platinum resistance. Drugs. 2000;59 Suppl 4:1-8; discussion 37-38.
- [4] Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, et al. The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res. 2014;33:37.
- [5] Pinciroli P, Alberti C, Sensi M, Canevari S, Tomassetti A. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response. BMC Genomics. 2013;14:508.
- [6] Semwal DK, Badoni R, Semwal R, Kothiyal SK, Singh GJ, Rawat U. The genus *Stephania* (Menispermaceae): chemical and pharmacological perspectives. J Ethnopharmacol. 2010;132(2):369-383.
- [7] Wongsirisin P, Yodkeeree S, Pompimon W, Limtrakul P. Induction of G1 arrest and apoptosis in human cancer cells by crebanine, an alkaloid from *Stephania venosa*. Chem Pharm Bull (Tokyo). 2012;60(10):1283-1289.
- [8] Yodkeeree S, Wongsirisin P, Pompimon W, Limtrakul P. Anti-invasion effect of crebanine and O-methylbulbocapnine from *Stephania venosa* via down-regulated matrix metalloproteinases and urokinase plasminogen activator. Chem Pharm Bull (Tokyo). 2013;61(11):1156-1165.
- [9] Yodkeeree S, Pompimon W, Limtrakul P. Crebanine, an aporphine alkaloid, sensitizes TNF- α -induced apoptosis and suppressed invasion of human lung adenocarcinoma cells A549 by blocking NF- κ B-regulated gene products. Tumour Biol. 2014;35(9):8615-8624.

- [10] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. *Int J Cancer*. 2015;136(5):E359-386.
- [11] Hinckley M. Ectopic pregnancy and IVF: Recent risk reduction. <https://rscbayarea.com/blog/ectopic-pregnancy-and-ivf> (accessed Jan 15, 2018).
- [12] Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, et al. Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments. *Aging Dis*. 2017;8(5):677-684.
- [13] Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. *Gynecol Oncol*. 2017.
- [14] Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. *Nat Rev Cancer*. 2017;17(1):65-74.
- [15] Vinay K, Abul A and Jon A, *Robbins Basic Pathology*, Elsevier, 9th Edition, 2012, 830, ISBN9780323286046.
- [16] Kommoss F, Gilks CB. Pathology of ovarian cancer: recent insights unveiling opportunities in prevention. *Clin Obstet Gynecol*. 2017;60(4):686-696.
- [17] Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. *Nat Commun*. 2017;8(1):990.
- [18] Sadlecki P, Antosik P, Grzanka D, Grabiec M, Walentowicz-Sadlecka M. Kras mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system. *Tumour Biol*. 2017;39(10):1010428317733984.
- [19] Anglesio MS, Yong PJ. Endometriosis-associated ovarian cancers. *Clin Obstet Gynecol*. 2017;60(4):711-727.
- [20] Sun L, Song Y, Li N, Yuan GW, Sun YC, Li N, et al. The clinicopathological features and risk factors of recurrence in patients with

- mucinous borderline ovarian tumors. *Chinese J Oncol*. 2017;39(8):589-594.
- [21] Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. *Gynecol Oncol*. 1999;72(3):278-287.
- [22] Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. *Cancer J Clin*. 1999;49(5):297-320.
- [23] Lowry KP, Lee SI. Imaging and screening of ovarian cancer. *Radiol Clin North Am*. 2017;55(6):1251-1259.
- [24] Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. *Br J Cancer*. 1994;70(2):363-370.
- [25] Kurtz AB, Tsimikas JV, Tempany CMC, Hamper UM, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis. *Radiology*. 1999;212(1):19-27.
- [26] Ozols RF. Update on the management of ovarian cancer. *Cancer J*. 2002;8 Suppl 1:S22-30.
- [27] Weiss RB, Christian MC. New cisplatin analogues in development. *Drugs*. 1993;46(3):360-377.
- [28] Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. *Expert Opin Investig Drugs*. 2010;19(11):1339-1354.
- [29] Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. *Mol Pharmacol*. 2006;70(4):1390-1394.
- [30] Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. *Crit Rev Oncol Hematol*. 2007;63(1):12-31.
- [31] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer*. 2002;2(1):48-58.
- [32] Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome

- following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. *Clin Cancer Res.* 2009;15(5):1645-1654.
- [33] Reed E. ERCC1 and clinical resistance to platinum-based therapy. *Clin Cancer Res.* 2005;11(17):6100-6102.
- [34] Li S, Li C, Jin S, Liu J, Xue X, Eltahan AS, et al. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. *Biomaterials.* 2017;144:119-129.
- [35] Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M. miRNA control of apoptotic programs: focus on ovarian cancer. *Expert Rev Mol Diagn.* 2011;11(3):277-286.
- [36] de Vries EGE, Gietema JA, de Jong S. Tumor necrosis factor-related apoptosis inducing ligand pathway and its therapeutic implications. *Clin. Cancer Res.* 2006;12(8):2390-2393.
- [37] Song K, Li Z, Seth P, Cowan KH, Sinha BK. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. *Oncol Res.* 1997;9(11-12):603-609.
- [38] Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M, et al. Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. *Chin J Cancer Res.* 2014;26(5):564-572.
- [39] Li Q, Lee RX, Liang H, Wang G, Li JM, Zhong Y, et al. β -Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. *Int J Oncol.* 2013;43(3):721-728.
- [40] Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick-Bruton F, et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. *Int J Oncol.* 1998;13(5):987-992.
- [41] Li Q, Tsang B, Bostick-Bruton F, Reed E. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. *Biochem Pharmacol.* 1999;57(4):347-353.

- [42] Westfall SD, Skinner MK. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. *Mol Cancer Ther.* 2005;4(11):1764-1771.
- [43] Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki S, Kakuda M, Okazawa A, et al. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. *Cancer Cell Int.* 2015;15:117.
- [44] O'Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. *Biochem J.* 2008;409(3):635-649.
- [45] Giuntoli RL, 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. *Anticancer Res.* 2009;29(8):2875-2884.
- [46] Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. *BMC Cancer.* 2011;11:210.
- [47] Nilsson MB, Langley RR, Fidler IJ. IL-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. *Cancer Res.* 2005;65(23):10794-10800.
- [48] Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. *Oncol Rep.* 2010;23(3):671-676.
- [49] Huang S, Chen M, Shen Y, Shen W, Guo H, Gao Q, et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. *Cancer Lett.* 2012;315(2):198-205.
- [50] Sheng WJ, Jiang H, Wu DL, Zheng JH. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer. *Braz J Med Biol Res.* 2013;46(8):650-658.
- [51] Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. *Biochem Biophys Res Commun.* 2013;435(2):188-194.

- [52] Jak/STAT signaling interactive pathway.
<https://www.cellsignal.com/contents/science-cst-pathways-immunology-and-inflammation/jak-stat-signaling-interactive-pathway/pathways-il6>
(accessed Jan 15, 2018).
- [53] Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol*. 2007;7(1):41-51.
- [54] Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, et al. Chemotherapy resistance induced by IL-6 in ovarian cancer cells and its signal transduction pathways. *Chinese J Oncol*. 2010;45(9):691-698.
- [55] Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. IL-6 as a therapeutic target in human ovarian cancer. *Clin Cancer Res*. 2011;17(18):6083-6096.
- [56] Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. *Frontiers in Genetics*. 2015;6:157.
- [57] Ozkan M, Akbudak IH, Deniz K, Dikilitas M, Dogu GG, Berk V, et al. Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. *Asian Pac J Cancer Prev*. 2010;11(1):181-185.
- [58] Xian-Jun F, Xiu-Guang Q, Li Z, Hui F, Wan-Ling W, Dong L, et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. *Pak J Med Sci*. 2014;30(3):488-492.
- [59] Steffensen KD, Smoter M, Waldstrom M, Grala B, Bodnar L, Stec R, et al. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. *Int J Oncol*. 2014;44(5):1736-1744.
- [60] Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S, et al. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. *Int J Cancer*. 2013;132(12):2778-2786.

- [61] Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. *Nat Rev Clin Oncol*. 2012;9(3):144-155.
- [62] Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. *J Biol Chem*. 1998;273(36):23419-23425.
- [63] Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. *J Clin Invest*. 1991;87(3):772-777.
- [64] Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. *J Nat Prod*. 2003;66(7):1022-1037.
- [65] Huq F, Yu JQ, Beale P, Chan C, Arzuman L, Nessa MU, et al. Combinations of platinum and selected phytochemicals as a means of overcoming resistance in ovarian cancer. *Anticancer Res*. 2014;34(1):541-545.
- [66] Ingkaninan K, Phengpa P, Yuenyongsawad S, Khorana N. Acetylcholinesterase inhibitors from *Stephania venosa* tuber. *J Pharm Pharmacol*. 2006;58(5):695-700.
- [67] Makarasen A, Sirithana W, Mogkhuntod S, Khunnawutmanotham N, Chimnoi N, Techasakul S. Cytotoxic and antimicrobial activities of aporphine alkaloids isolated from *Stephania venosa* (Blume) Spreng. *Planta Med*. 2011;77(13):1519-1524.
- [68] Nantapap S, Loetchutinat C, Meepowpan P, Nuntasaen N, Pompimon W. Antiproliferative effects of alkaloids isolated from the tuber of *Stephania venosa* via the induction of cell cycle arrest in mammalian cancer cell lines. *Am J Appl Sci*. 2010;7(8):1057-1065.
- [69] Wang H, Cheng X, Kong S, Yang Z, Wang H, Huang Q, et al. Synthesis and structure-activity relationships of a series of aporphine derivatives with antiarrhythmic activities and acute toxicity. *Molecules*. 2016;21(12).
- [70] Le PM, Srivastava V, Nguyen TT, Pradines B, Madamet M, Mosnier J, et al. Stephanine from *Stephania venosa* (Blume) Spreng showed effective


- antiplasmodial and anticancer activities, the latter by inducing apoptosis through the reverse of mitotic exit. *Phytother Res.* 2017;31(9):1357-1368.
- [71] Sun S, Chen Z, Li L, Sun D, Tian Y, Pan H, et al. The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. *Xenobiotica.* 2012;42(12):1197-1205.
- [72] Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res.* 2010;70(2):440-446.
- [73] Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. *Curr Cancer Drug Targets.* 2009;9(3):307-319.
- [74] Vassilopoulos A, Xiao C, Chisholm C, Chen W, Xu X, Lahusen TJ, et al. Synergistic therapeutic effect of cisplatin and phosphatidylinositol 3-kinase (PI3K) inhibitors in cancer growth and metastasis of Brca1 mutant tumors. *J Biol Chem.* 2014;289(35):24202-24214.
- [75] Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF- κ B in development and progression of human cancer. *Virchows Arch.* 2005;446(5):475-482.
- [76] Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). *Int J Oncol.* 2009;34(4):881-895.
- [77] Lederle W, Depner S, Schnur S, Obermueller E, Catone N, Just A, et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. *Int J Cancer.* 2011;128(12):2803-2814.
- [78] Zeng F, Wei H, Yeoh E, Zhang Z, Ren ZF, Colditz GA, et al. Inflammatory Markers of CRP, IL6, TNF α , and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies. *Cancer Epidemiol Biomarkers Prev.* 2016;25(8):1231-1239.
- [79] Sanguinete MMM, Oliveira PH, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, et al. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer. *Immunol Invest.* 2017;46(7):677-688.
- [80] Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. *Int J Cancer.* 2002;99(2):157-166.

- [81] Jia ZH, Jia Y, Guo FJ, Chen J, Zhang XW, Cui MH. Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer. *PLoS One*. 2017;12(8):e0183622.
- [82] Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. *Mol Cancer Ther*. 2014;13(12):3037-3048.
- [83] Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. *J Clin Invest*. 2007;117(12):3988-4002.
- [84] Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. *Clin Cancer Res*. 2006;12(17):5055-5063.
- [85] Judd LM, Alderman BM, Howlett M, Shulkes A, Dow C, Moverley J, et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. *Gastroenterology*. 2004;126(1):196-207.
- [86] Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. *J Clin Invest*. 2004;114(5):720-728.
- [87] Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. *Drug Resist Updat*. 2004;7(4-5):227-232.
- [88] Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. *J Exp. Clin Cancer Res*. 2011;30(1):87-87.
- [89] Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy. *Taiwan J Obstet Gynecol*. 2009;48(3):239-244.
- [90] Gottesman MM. Mechanisms of cancer drug resistance. *Annu Rev Med*. 2002;53:615-627.

- [91] Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. *Oral oncology*. 2016;56:84-92.
- [92] Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, et al. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. *J Chem Biol*. 2017;10(3):129-141.
- [93] Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. *Chin J Cancer*. 2015;34(1):4-16.
- [94] Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, et al. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. *Oncol Rep*. 2012;28(6):2023-2028.
- [95] Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. *J Biol Chem*. 2003;278(21):19245-19256.
- [96] Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. *Int J Cancer*. 2004;112(6):974-985.
- [97] St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J. Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. *Neoplasia*. 2010;12(7):527-538.
- [98] Peng DJ, Wang J, Zhou JY, Wu GS. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. *Biochem Biophys Res Commun*. 2010;394(3):600-605.
- [99] Sethi G, Sung B, Aggarwal BB. NFkB activation: from bench to bedside. *Exp Biol Med (Maywood)*. 2008;233(1):21-31.

- [100] Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of IL-6-type cytokine signalling and its regulation. *Biochem J*. 2003;374(Pt 1):1-20.
- [101] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008;454(7203):436-444.
- [102] Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, et al. Inhibition of constitutively active STAT3 suppresses growth of human ovarian and breast cancer cells. *Oncogene*. 2001;20(55):7925-7934.
- [103] Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription factor STAT3 as a novel molecular target for cancer prevention. *Cancers (Basel)*. 2014;6(2):926-957.
- [104] Lesina M, Wormann SM, Neuhofer P, Song L, Algul H. IL-6 in inflammatory and malignant diseases of the pancreas. *Semin Immunol*. 2014;26(1):80-87.
- [105] Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. STAT3 pathway activation in drug-resistant ovarian cancer. *Clin Cancer Res*. 2006;12(17):5055-5063.
- [106] Torng PL, Mao TL, Chan WY, Huang SC, Lin CT. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. *Gynecol Oncol*. 2004;92(2):559-567.
- [107] Rasool M, Malik A, Basit Ashraf MA, Parveen G, Iqbal S, Ali I, et al. Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer. *PLoS One*. 2016;11(11):e0167149.
- [108] Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. *J Clin Oncol*. 2011;29(14):1916-1923.
- [109] Schilsky RL. Personalized medicine in oncology: the future is now. *Nat Rev Drug Discov*. 2010;9(5):363-366.


- [110] Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. *Cancer Res.* 2011;71(2):424-434.
- [111] Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. *Eur Cytokine Netw.* 2013;24(3):106-113.
- [112] Lippitz BE, Harris RA. Cytokine patterns in cancer patients: A review of the correlation between IL-6 and prognosis. *Oncoimmunology.* 2016;5(5):e1093722.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
 Copyright© by Chiang Mai University
 All rights reserved

LIST OF PUBLICATIONS

- 1) Mon MT, Yodkeeree S, Punfa W, Umsumarng S, Lekwanavijit S, Siriaunkgul S, Suprasert P and Limtrakul P. Relationships of *ex-vivo* drug resistance assay and cytokine production with clinicopathological features in the primary cell culture of Thai ovarian and fallopian tube cancer patients. *Asian Pac J Cancer Prev*. 2017;18(11):3063-3071.
- 2) Mon MT, Yodkeeree S, Punfa W, Pompimon W and Limtrakul P. Alkaloids from *Stephania venosa* as chemo-sensitizers in SKOV3 ovarian cancer cells via Akt/NF- κ B signaling. *Chem Pharm Bull (Tokyo)*. 2018;66(2).



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved